Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial. // ESMO Open. – URL: https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all
Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial. ESMO Open. https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all
“Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial.” ESMO Open.
@article{article98952,
title = {Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial},
journal = {ESMO Open},
url = {https://www.sciencedirect.com/science/article/pii/S2059702926025822?dgcid=rss_sd_all}
}